% Expired Patents = 100.0

Forward Citations = 25

Loading Chart...

3 inventors (with patents filed for the assignee):

J Curtis Nickel (2 out of 3 patents)

J Thomas Buckley (1 out of 4 patents)

James Thomas Buckley (1 out of 4 patents)

4 patents: Sort by Forward Citations

1. 10654900 - Method for treating prostatitis utilizing the pore-forming protein proaerolysin PRX302 (2020-05-19),

2. 9950029 - Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins (2018-04-24),

3. 8916161 - Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins (2014-12-23),

4. 8901070 - Pharmaceutical compositions comprising pore-forming proaerolysin protein (PRX302) (2014-12-02),

Company Overview

Sophiris Bio Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of urological diseases. The company's lead product candidate, PRX302, is in clinical development for the treatment of localized prostate cancer and benign prostatic hyperplasia (BPH). Sophiris Bio is dedicated to improving the lives of patients suffering from these conditions through innovative therapies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

4 Patents

#221 in Vancouver

#3,466 in Canada

Vancouver, Canada

Sophiris Bio Inc.

Forward Citations = 25

3 inventors:

J Curtis Nickel (2 out of 3 patents)

J Thomas Buckley (1 out of 4 patents)

James Thomas Buckley (1 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sophiris Bio Inc.. Retrieved from https://idiyas.com/company/sophiris-bio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]